This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weir, L. Articles by Olivotto, I. A. Search for Related Content PubMed PubMed Citation Articles by Weir, L. Articles by Olivotto, I. A. Social Bookmarking                            What's this?

Prognostic Significance of the Number of Axillary Lymph Nodes Removed in Patients With Node-Negative Breast Cancer

From the Radiation Therapy Program, Breast Cancer Outcomes Unit, and Population and Preventive Oncology, British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada.

Address reprint requests to L. Weir, MD, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, British Columbia V5Z 4E6, Canada; email: lweir{at}bccancer.bc.ca

PURPOSE: The objective of the study was to evaluate the association between the number of lymph nodes removed at axillary dissection and recurrence and survival for patients with node-negative invasive breast cancer.

PATIENTS AND METHODS: Subjects were 2,278 women with pathologically node-negative invasive breast cancer, diagnosed from 1989 to 1993 in British Columbia, Canada. Women aged 90 years, with pure in-situ, bilateral invasive breast cancer or T4, N1, N2, or M1 stage, or who had axillary radiation were excluded. Two groups were defined for analysis: node-negative with no systemic therapy (n = 1,468) and node-negative with systemic therapy (n = 810). Median follow-up was 7.5 years. Prognostic variables assessed were age at diagnosis, tumor size, tumor grade, invasion of lymphatics, veins, or nerves, estrogen receptor status, and number of nodes removed.

RESULTS: For patients not receiving systemic therapy, regional relapse was significantly increased with smaller numbers of nodes removed (P = .03). There was a trend toward shorter overall survival with fewer nodes removed (P = .06). Node-negative patients who received systemic therapy did not have a higher regional relapse rate or shorter overall survival when fewer nodes were recovered.

CONCLUSION: Recovery of a small number of negative lymph nodes at axillary dissection likely understages patients and leads to undertreatment, resulting in an increased regional relapse rate and poorer survival. The use of systemic therapy may overcome this effect. The number of nodes removed, in conjunction with other prognostic factors, may be useful in selecting node-negative patients for systemic therapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. S. Dabakuyo, F. Bonnetain, P. Roignot, M.-L. Poillot, G. Chaplain, T. Altwegg, G. Hedelin, and P. Arveux Population-based study of breast cancer survival in Cote d'Or (France): prognostic factors and relative survival Ann. Onc., February 1, 2008; 19(2): 276 - 283. [Abstract] [Full Text] [PDF]

				J. G. Lee, C. Y. Lee, I. K. Park, D. J. Kim, S. Y. Park, K. D. Kim, and K. Y. Chung Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Ann. Thorac. Surg., January 1, 2008; 85(1): 211 - 215. [Abstract] [Full Text] [PDF]

				I Blancas, J. Garcia-Puche, B Bermejo, E. Hanrahan, C Monteagudo, A Martinez-Agullo, R Rouzier, B. Hennessy, V Valero, and A Lluch Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor Ann. Onc., November 1, 2006; 17(11): 1644 - 1649. [Abstract] [Full Text] [PDF]

				I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum Primary Systemic Therapy of Breast Cancer Oncologist, June 1, 2006; 11(6): 574 - 589. [Abstract] [Full Text] [PDF]

				A. C. Berger, E. R. Sigurdson, T. LeVoyer, A. Hanlon, R. J. Mayer, J. S. Macdonald, P. J. Catalano, and D. G. Haller Colon Cancer Survival Is Associated With Decreasing Ratio of Metastatic to Examined Lymph Nodes J. Clin. Oncol., December 1, 2005; 23(34): 8706 - 8712. [Abstract] [Full Text] [PDF]

				M. S. Ludwig, M. Goodman, D. L. Miller, and P. A. S. Johnstone Postoperative Survival and the Number of Lymph Nodes Sampled During Resection of Node-Negative Non-Small Cell Lung Cancer Chest, September 1, 2005; 128(3): 1545 - 1550. [Abstract] [Full Text] [PDF]

				I. A. Olivotto, C. D. Bajdik, P. M. Ravdin, C. H. Speers, A. J. Coldman, B. D. Norris, G. J. Davis, S. K. Chia, and K. A. Gelmon Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer J. Clin. Oncol., April 20, 2005; 23(12): 2716 - 2725. [Abstract] [Full Text] [PDF]

				J E A Somner, J M J Dixon, and J S J Thomas Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to be confident about node negative status J. Clin. Pathol., August 1, 2004; 57(8): 845 - 848. [Abstract] [Full Text] [PDF]

				Y. Nieto, S. Nawaz, E. J. Shpall, S. I. Bearman, J. Murphy, and R. B. Jones Long-Term Analysis and Prospective Validation of a Prognostic Model for Patients with High-Risk Primary Breast Cancer Receiving High-Dose Chemotherapy Clin. Cancer Res., April 15, 2004; 10(8): 2609 - 2617. [Abstract] [Full Text] [PDF]

				A. Gajra, N. Newman, G. P. Gamble, L. J. Kohman, and S. L. Graziano Effect of Number of Lymph Nodes Sampled on Outcome in Patients With Stage I Non-Small-Cell Lung Cancer J. Clin. Oncol., March 15, 2003; 21(6): 1029 - 1034. [Abstract] [Full Text] [PDF]

				I. A. Olivotto, B. Chua, S. J. Allan, C. H. Speers, S. Chia, and J. Ragaz Long-Term Survival of Patients With Supraclavicular Metastases at Diagnosis of Breast Cancer J. Clin. Oncol., March 1, 2003; 21(5): 851 - 854. [Abstract] [Full Text] [PDF]